In this video, health care analysts David Williamson and Max Macaluso discuss Vertex's recent tie up with two deep-pocketed members of big pharma. Although Vertex currently owns the standard of care for hepatitis C treatments, it isn't sitting on its laurels. Watch and find out what this new deal means for Vertex, its partners, and its competitors.
Motley Fool Returns
Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.
Stock Advisor launched in February of 2002. Returns as of 10/20/2021.
Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
- Why Are Investors Ignoring Vertex's Good News?
- If You Invested $5,000 in Vertex Pharmaceuticals In 2016, This Is How Much You Would Have Today
- 3 No-Brainer Stocks to Invest $500 In Right Now
- 2 Stocks You'll Probably Never Want to Sell
- 3 Highly Profitable Stocks Wall Street Thinks Will Soar 39% or More